Biosimilars set to drive significant savings in healthcare systems News item 09 April 2016 Pages: 3 - 3
Apremilast cost effective for severe plaque psoriasis in UK Clinical study 09 April 2016 Pages: 11 - 11
Barriers to use of economic evidence for pricing decisions Clinical study 09 April 2016 Pages: 12 - 12
CAM often used but not disclosed to primary care physicians Clinical study 09 April 2016 Pages: 13 - 13
Financial incentives for preschool vax not acceptable in UK Clinical study 09 April 2016 Pages: 15 - 15
Financial incentives reduce high-risk prescribing and hospitalisation Clinical study 09 April 2016 Pages: 16 - 16
Flucytosine cost effective in US despite increase in drug cost Clinical study 09 April 2016 Pages: 17 - 17
Infliximab not cost effective for ulcerative colitis in Poland Clinical study 09 April 2016 Pages: 19 - 19
Long-acting paliperidone cost saving for schizophrenia in Spain Clinical study 09 April 2016 Pages: 20 - 20
Management of indigenous Australian T2DM pts disappointing Clinical study 09 April 2016 Pages: 21 - 21
Minimal extra cost with enhanced mental health care pathways in UK Non-clinical study 09 April 2016 Pages: 22 - 22
Neurologists' Medicare Part D payments highest for MS drugs Clinical study 09 April 2016 Pages: 23 - 23
Observers willing to pay for plastic surgery for facial defects Clinical study 09 April 2016 Pages: 24 - 24
Same-day CRT/ICD implantation cost saving, feasible, safe Clinical study 09 April 2016 Pages: 32 - 32
WTP for smoking cessation aids below market price in Germany Clinical study 09 April 2016 Pages: 34 - 34